Abstract
Increasing evidence suggests that glycogen synthase kinase-3β (GSK-3β) plays a crucial role in neurodegenerative/psychiatric disorders, while pan-neural knockout of GSK-3β also shows detrimental effects. Currently, the function of GSK-3β in specific type of neurons is elusive. Here, we infused AAV-CaMKII-Cre-2A-eGFP into GSK-3βlox/lox mice to selectively delete the kinase in excitatory neurons of hippocampal dentate gyrus (DG), and studied the effects on cognitive/psychiatric behaviors and the molecular mechanisms. We found that mice with GSK-3β deletion in DG excitatory neurons displayed spatial and fear memory defects with an anti-anxiety behavior. Further studies demonstrated that GSK-3β deletion in DG subset inhibited hippocampal synaptic transmission and reduced levels of GluN1, GluN2A and GluN2B (NMDAR subunits), GluA1 (AMPAR subunit), PSD93 and drebrin (postsynaptic structural proteins), and synaptophysin (presynaptic protein). GSK-3β deletion also suppressed the activity-dependent neural activation and calcium/calmodulin-dependent protein kinase II (CaMKII)/CaMKIV-cAMP response element binding protein (CREB) signaling. Our data suggest that GSK-3β in hippocampal DG excitatory neurons is essential for maintaining synaptic plasticity and memory.
Similar content being viewed by others
Introduction
Glycogen synthase kinase-3 (GSK-3) is highly expressed in central nervous system. Of the two isoforms of GSK-3, i.e. GSK-3α and GSK-3β, activation of GSK-3β is involved in neurodegenerative and psychiatric disorders1,2,3. For instance, elevation of the active form of GSK-3β has been shown in tangle-bearing neurons of the patients with Alzheimer’s disease (AD)4. Both in vitro and in vivo studies demonstrate that upregulation of GSK-3β induces AD-like hyperphosphorylation of microtubule-associated protein tau and causes memory deficit, while inhibition of GSK-3 attenuates tau hyperphosphorylation with improvement of cognitive synaptic functions5,6,7,8,9,10. Thus inhibition of GSK-3β has been considered as a potential therapeutic target of neurodegenerative and psychiatric disorders9, 11,12,13,14,15.
However, GSK-3β has diverse physiological functions related to neurogenesis, intracellular signaling, synaptic plasticity and neuronal viabilities16,17,18,19. In hippocampus, GSK-3β is required for induction of long term depression (LTD)20. Activation of GSK-3β enhances spontaneous firing rate (SFR)21 and contributes to neuronal excitability22. GSK-3β knockout causes embryonic lethality in murine23, and global heterozygous GSK-3β knockout in mice induces long-term spatial memory impairment24. In neuronal levels, loss of GSK-3β reduces dendritic spine stability with an impaired synaptic transmission in cortices and hippocampal CA1 subset25. These data suggest that global knockout of GSK-3β also causes negative effects.
The trisynaptic circuit in hippocampus formation (i.e. entorhinal cortex (EC) to dentate gyrus (DG)/DG to CA3/CA3 to CA1) is essential for spatial memory and emotional behaviors26,27,28,29. The excitatory neuron in DG is crucial for encoding of contextual information30,31,32. Although a previous study has shown that pan-neuronal silence of GSK-3β in adult DG impairs contextual fear memory with an enhanced LTP33, the function of GSK-3β in DG excitatory neuron is not reported.
In the present study, we designed an adenovirus-associated virus vector (AAV-CaMKII-Cre-2A-eGFP) to specifically delete GSK-3β in hippocampal DG excitatory neurons of GSK-3β floxed mice (GSK-3βlox/lox)34. We found that GSK-3β deletion in hippocampal DG excitatory neurons induced spatial and fear memory deficits with an anti-anxiety behavior. The molecular mechanism involves CaMKII/CaMKIV/CREB signaling-associated synaptic impairments.
Results
Deletion of GSK-3β in DG excitatory neurons in GSK-3βlox/lox mice
To investigate the function of GSK-3β in DG excitatory neurons, we first infused stereotaxically AAV-CaMKII-Cre-2A-eGFP (Cre recombinase) or its empty vector (as control) (Fig. 1a) into the hippocampal DG subset of GSK-3βlox/lox mice to induce a specific deletion of GSK-3β in DG excitatory neurons. The expression of the virus vector in hippocampal DG and the Mossy fibers was detected by direct fluorescence imaging at 4 weeks after infusion of the Cre recombinase (Fig. 1b, Supplementary Fig. 1). A significant reduction of GSK-3β protein level was confirmed by Western blotting (Fig. 1c,d) with a remarkable decrease of GSK-3β activity in DG subset (Fig. 1e). Immunohistochemistry data showed that expression of Cre recombinase almost completely deleted GSK-3β expression in hippocampal DG (Fig. 1f, Supplementary Fig. 2), and specific deletion of GSK-3β in DG excitatory neurons was confirmed by co-immunofluorescence staining of GFP with CaMKII but not GAD67 (Fig. 1g,h). No significant change of GSK-3α protein level was detected (Fig. 1i,j). These data demonstrate an effective and specific deletion of GSK-3β in hippocampal DG of GSK-3βlox/lox mice by Cre recombinase.
GSK-3β deletion in DG excitatory neurons induces spatial and fear memory deficits
The hippocampal DG subset is critical in spatial and fear memory30, 35, 36. Therefore, we first measured spatial memory of the mice by MWM test. During the first 6 days training sections, we did not observe significant difference in latency to find the submerged platform between two groups (Fig. 2a). However, the mice with GSK-3β deletion showed decreased time spent in the target quadrant and a decreased platform crossing in the probe trial during spatial memory test (Fig. 2b,c). In contextual fear memory test, GSK-3β deletion did not change freezing response during training test, but the freezing time was remarkably decreased during contextual memory test measured at 24 h after (Fig. 2e,f). These data indicate that GSK-3β deletion in DG excitatory neurons impairs spatial and contextual memory without significantly changing learning ability of the mice. As hippocampal DG subset and GSK-3β are closely involved in anxiety37,38,39, we also measured the anxiety behavior. The results showed that GSK-3β deletion in DG excitatory neurons significantly decreased corner duration in open field test (Fig. 3a–d), and increased the staying time in open arm during elevated maze test (Fig. 3e–h). These data suggest that GSK-3β deletion can decrease anxiety level.
GSK-3β deletion decreases synapse proteins and impairs synaptic plasticity
Synaptic plasticity, including expression of synaptic related proteins, spine density and morphology, and the functional neuronal transmission, is the precondition of cognitive abilities40, 41. To explore the mechanisms that may underlie the behavioral impairments induced by GSK-3β deletion, we measured the levels of synaptic proteins. By unpaired t-test analysis, we observed that GSK-3β deletion remarkably decreased the levels of GluN1, GluN2A and GluN2B (NMDAR subunits), GluA1 (AMPAR subunit), PSD93 and drebrin (postsynaptic structural proteins), and synaptophysin (presynaptic protein) in DG subset (Fig. 4a,b), while the levels of these proteins were not changed in the prefrontal cortex (Fig. 4c,d). By using multiple comparisons, the difference of GluN2A, GluN2B, drebrin and synaptophysin reductions was still significant (Fig. 4a,b). No significant neuron loss was shown upon GSK-3β deletion in DG subset measured by Nissl staining and densitometric analyses (Fig. 4e,f).
By electrophysiological recording on acute brain slices, the basal synaptic transmission and LTP induction from DG to CA3 subset were inhibited upon GSK-3β deletion (Fig. 5a–c). GSK-3β deletion also decreased the number of dendritic spine in DG excitatory neurons measured by z-stack scanning under a two-photon fluorescence microscope (Fig. 5d,e), while the GSK-3β deletion in DG did not affect the spine density in prefrontal cortex (Fig. 5f,g). To further explore the mechanisms that may underlie the synapse impairments, we measured neural activity by c-fos staining. The number of c-fos-positive neurons in DG and basal lateral amygdala (BLA) subsets was significantly decreased (Fig. 5h–j). As a negative control, no difference of c-fos-positive neurons was observed in subset of paraventricular thalamic nucleus (PV) in GSK-3β deletion group (Fig. 5h,k). These data together suggest that GSK-3β deletion in DG excitatory neurons impairs synaptic plasticity and arrests the activity-dependent neural activation in DG and BLA.
GSK-3β deletion inhibits CaMKII/IV-CREB signaling
The CaMKII/IV-CREB signaling plays a crucial role in synapse-associated protein expression42, 43. Therefore, we also measured the effects of GSK-3β deletion on CaMKII/IV-CREB signaling. We observed that the total protein level and/or the phosphorylated levels of CREB, CaMKII and CaMKIV were all decreased in GSK-3β deleted DG subset of the hippocampus and reduction of the phosphorylation (the active forms) was more significant, in which pCREB was almost completely diminished (Fig. 6a,b). Significant reduction of pCREB in hippocampal DG was also detected by immunofluorescence staining in GSK-3β deletion group (Fig. 6c). These data suggest that GSK-3β deletion in DG may inhibit expression of synaptic proteins with CaMKII/IV-CREB-associated mechanisms.
Discussion
As GSK-3β knockout in mouse is lethal during the embryonic period23, pharmacological inhibitors44,45,46 and shRNA-mediated silencing33 have been widely used to downregulate the kinase in previous studies. The transgenic approaches have also been employed to knockdown GSK-3β in pan-neurons24, 25. By using Cre-loxp system, this is the first report showing that selective deletion of GSK-3β in hippocampal DG excitatory neurons induces spatial and fear memory deficits, and the mechanisms involves inhibition of CaMKII/CaMKIV/CREB signaling-related neural activation and synaptic plasticity.
GSK-3β is abundantly expressed in hippocampus47. In hippocampal formation, CA3 subset plays important role in encoding new spatial information, which requires multiple trial learning and short-term memory retrieval based on a spatial pattern completion process, while the CA1 subset receives incoming information from CA3 and sets up associatively learned back projections to entorhinal cortex that is consistent on consolidation48. We choose to delete GSK-3β in DG because it is a critical subset for spatial and fear memory and for psychiatric behaviors36, 49,50,51. In MWM test, we observed no significant difference between groups in the training section, but the mice with GSK-3β deletion displayed memory impairment in the probe trials. In contextual fear conditioning test, GSK-3β deletion did not affect the foot shock response during training, but severely impaired the fear memory. In a previous report, DG pan-neuronal GSK-3β knockdown by lentivirus did not alter the memory in MWM test33. We speculate that the excitatory neuron-specific deletion of GSK-3β versus pan-neuronal manipulation may explain the discrepancy. Additionally, the AAV used in the current paper achieved ~74% knockdown in the excitatory neurons, while the lentivirus employed in the previous paper only achieved ~20% knockdown of GSK-3β in pan-neurons.
Neuronal excitation and the Ca2+ signaling pathway are the bases of neural transmission and the activity-dependent protein synthesis42, 43, 52. Previous studies demonstrate that GSK-3β is critical for rhythms-related neuronal activity22. GSK-3β affects endocytosis and exocytosis5, 53. Hence, we hypothesize that GSK-3β knockout may alter neuronal activity in response to the cognitive manipulations. Our results did show that neuron activation during fear memory was mainly located in DG, however, the number of c-fos-positive neurons was markedly decreased by GSK-3β deletion. This result indicates that GSK-3β deletion alters the neuronal activity in DG during learning and memory. GSK-3β deletion did not induce significant cell loss measured by Nissl staining. Nonetheless, we do not exclude the possibility that the compromised neuronal survival by GSK-3β deletion could be compensated by an increased neurogenesis in the region. Indeed, inhibition of GSK-3 has been shown to stimulate adult neurogenesis54. Therefore, a higher turnover of DG granule cells in GSK-3β conditional deletion may be present, which deserves further investigation.
We also observed that the neuronal activity in BLA, a region related with fear memory55, significant decreased in mice with GSK-3β deletion in DG excitatory neurons. Currently, it is not known whether BLA receives axonal projections from DG. However, as hippocampal trisynaptic circuit (DG-CA3-CA1) involves CA129 and BLA receives axonal projection form CA156, by which DG and BLA subsets may have indirect connection, and GSK-3β deletion in DG excitatory neurons may impair this connection.
CaMKII/IV is related with the complexity of neuronal dendritic spines57, 58. We observed that selective deletion of GSK-3β in DG excitatory neurons inhibited CaMKII activity with reduction of total and the phosphorylated CaMKIV. It is currently not understood how GSK-3β deletion leads to suppression of CaMKII/IV. As CREB is robustly phosphorylated by CaMKII and CaMKIV, which regulates the transcription of neuronal activity-related proteins42, 43, we speculate that cross-talk of CAMKII/IV and CREB inhibition may at least contribute to the significantly reduced expression levels of multiple synaptic proteins. We also noticed that GSK-3β deletion did not significantly change the expression levels of GluA2 and PSD95, suggesting that GSK-3β may regulate different synapse-associated proteins with distinct mechanisms, which may be investigated in future studies.
Previous studies demonstrate that GSK-3β activation inhibits LTP induction6, while pharmacological inhibition and lentivirus silencing of GSK-3β potentiates LTP33, 59. Here, we observed that selective deletion of GSK-3β impaired dendrite density in DG excitatory neurons with inhibition of LTP induction from DG to CA3, suggesting that GSK-3β in DG excitatory neurons plays a critical role in dendrite development and presynaptic transmission of DG-CA3. With regard to GSK-3β on LTP, it was also reported previously that pharmacological blockade of the hyperactivated GSK-3β by lithium or SB216763 or transient expression of a dominant-negative GSK-3β mutant attenuated LTP deficits of from medial perforant path (MPP) input to DG or MPP-CA3 or Schaffer collateral (SC) synapses in CA1 pathways in Fragile-X mice59 or in rats6 or mice60. On the other hand, Chew et al. reported that knockdown of GSK-3β by expressing lenti-ShRNA in DG pan-neuronal cells enhanced postsynaptic LTP from MPP input to DG33. We speculate that the following differences may at least partially explain the discrepancy: (i) non-specific pan-neuronal partial knockdown (~20%) of GSK-3β in previous study versus specific excitatory neuronal deletion in current paper. (ii) the postsynaptic LTP of MPP-DG or MPP-CA3 measured by previous study versus presynaptic LTP of DG-CA3 measured in current paper, which may represent different synaptic plasticity61. A most recent study shows that GSK-3β deletion impairs the amplitude and frequency of AMPAR-dependent synaptic currents25, which supports our current finding. Nonetheless, the pharmacological approaches and shRNA experiments could be more acute than conditional deletion, while the latter may induce risk of measuring secondary effects of GSK-3β deletion.
Taken together, we have observed that selective deletion of GSK-3β in DG excitatory neurons induces memory deficit and anxiety-like behavior with mechanisms involving impaired synaptic plasticity and neural inactivation.
Materials and Methods
Animals, viruses, and stereotaxic surgery
The GSK-3β floxed mouse (GSK-3βlox/lox) is a kind gift of Dr. James R Woodgett34. The mice were housed under a 12-h light/dark cycle and kept with accessible food and water at 25 °C. All animal studies were approved by the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology. The AAV-CaMKII-Cre-2A-eGFP vector was designed for the specific expression of Cre recombinase with non-fusion eGFP in excitatory neurons. For brain injection, the mice (2m-old) were fixed in the stereotaxic apparatus (DAVID kopf instruments) and anesthetized with Isoflurane (2.0% for induction and 1.5% for maintenance). After being sterilized with iodophors, the scalp was incised along skull midline and holes were drilled in the hibateral stereotaxically at posterior 1.9 mm, lateral 1.1 mm, and ventral 2.0 mm relative to bregma. Using an automatic microinjection system (World Precision Instruments), AAV-CaMKII-Cre-2A-eGFP or the empty vector (1 μl, 4.0 × 1012 viral particles per ml) was injected into the hippocampus DG region at a rate of 0.1 μl/min with Hamilton needle, the needle was kept in place for 10 min before slowly pull out, the skin was sutured, and sterilized with iodophors, and the mice were placed in thermo tank for analepsia. At 4 weeks after brain infusion of the virus, the behaviors were measured as described as follows.
Morris water maze (MWM) test
The MWM test was performed as described in a previous study62, 63. The mice were trained to find a hidden platform which submerged under milk water for six consecutive days, three trials per day, and cues outside the pool were constant. During each trial, the mouse started from one of three quadrants (exclude target quadrant) facing the wall of the pool and find the hidden platform in 60 s, after which they were guided to the platform and placed for 20 s. The swimming path and latency were recorded in each trail by a digital video camera connected to a computer (Chengdu Taimeng Software Co. Lid, China). On the 8th day, the mice were allowed to swim for 60 s without the hidden platform. The time stayed in the previous target quadrant and the number of the target platform crossings was recorded.
Contextual fear conditioning
The mice were placed into the conditioning chamber and allowed to explore the conditioning chamber for 3 min. Then they received three times electric foot shocks (0.8 mA, 2 s each, and 1 min rest in between), and then they were returned to home cages. The chambers were cleaned with 75% alcohol before the next mouse was trained. After 24 h, the mice were placed back into the conditioning chamber for 3 min without electric foot shock. The activity and freezing behavior were recorded by a video tracking system (Chengdu Taimeng Software Co. Lid, China).
Open field test
The Open-Field test consisted of a 5-min session in one 50 × 50 cm chamber (white opaque plastic), which was divided into 25 square regions, a central field (center 9 square regions, 15 × 15 cm2) and a periphery field. Each mouse was placed in the same periphery region at the start of the test. Behaviors were recorded and analyzed by the video tracking system (Chengdu Taimeng Software Co. Lid, China).
Elevated plus maze
The Elevated plus maze test was performed as described in a previous study64. Briefly, mice were placed at the junction of the four arms of the maze (white opaque plastic), and the starting test was faced an open arm. The chambers were cleaned with 75% alcohol before the next mouse was trained. And the entries and/or duration in each arm were recorded for 5 min by the video tracking system (Chengdu Taimeng Software Co. Lid, China). An increase in open arm activity (duration and/or entries) reflects anti-anxiety behavior.
For animal studies, the mice (all had the same gene background) were randomly divided into experimental and the control groups and the behavioral tests were carried by the same operators who were blind of the treatments the mice received. After behavior tests, the virus expression and the location were confirmed by fluorescence microscopy. The mice lacking robust virus expression or having virus spreading onto the other brain regions were discarded from behavioral data analysis (~20%).
Western blotting
The western blotting was performed as described in a previous study62. The mice were anesthetized with an i.p. injection of 100 mg/kg of ketamine and 50 mg/kg of xylazine. The mice brains sectioned (300-μm-thick) using vibrating microtome (Leica, VT1000 S, Germany) on ice-cold PBS, and the hippocampus DG subset was accurately separated according to the mouse brain atlas. The proteins of hippocampus DG were extracted using RIPA buffer (P0013B, Beyotime) and the concentration was determined by BCA method. Equal amount of proteins were separated by 10% SDS–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto the nitrocellulose membranes, blocked with 5% skim milk for 1 h at room temperature, and then incubated with primary antibodies (Table 1) for 2 h at room temperature or overnight at 4 °C. The bands were visualized by using Odyssey Infrared Imaging System (LI-COR biosciences, Lincoln, NE, USA). The protein of hippocampal extracts loaded for Western blotting was 15 μg for GSK-3β and GSK-3α; 10 μg for synapsin I, synaptotagmin, synaptophysin; 5 μg for β-actin; 30 μg for GluN1; and 20 μg for other proteins. For cortex analysis, 30 μg for GluN2A, GluN2B, GluA1 and GluA2; and 20 μg for all other proteins.
Immunohistochemistry and immunofluorescence
The mice were anesthetized with an i.p. injection of 100 mg/kg of ketamine and 50 mg/kg of xylazine, and transcardially perfused with normal saline (NS), followed by 4% paraformaldehyde (PFA) for 30 min. Brains were removed and post-fixed for additional 48 h. After that, the brains were sliced 30 μm with a vibrating microtome (VT1000S, Leica, Germany). The brain slices permeabilized in phosphate buffer containing 0.5% Triton X-100, 3% H2O2 for 30 min, then blocked by 3% BSA for 30 min. The slices were incubated with primary antibody shown in Table 1 for overnight at 4 °C, followed by a horseradish peroxidase-labeled antibody for 1 h at 37 °C, and exposed to DAB. The images were observed under a microscope (Nikon, 90i, Tokyo, Japan). The c-fos staining was analyzed in BLA (Coronal section, −1.4 mm Bregma). For immunofluorescence, the brain slices were incubated with donkey anti-Rabbit IgG (H + L) secondary antibody alexa Fluor 546 (ThermoFisher Scientific, A10040) for 1 h at room temperature, and the images were observed with a laser confocal microscope (710; Zeiss, Germany).
Nissl staining
The mice were anesthetized with an i.p. injection of 100 mg/kg of ketamine and 50 mg/kg of xylazine, and were fixed by perfusing 4% paraformaldehyde solution through heart. The brain was removed and post-fixed in the same fixative solution for overnight at 4 °C. Coronal sections (30 μm thickness) were prepared by using vibratome. The sections were submerged in 0.5% cresyl violet solution for about 1 min.
Electrophysiology
Mice were deeply anesthetized with an i.p. injection of 100 mg/kg of ketamine and 50 mg/kg of xylazine, and the brains were immediately removed and immersed in ice-cold oxygenated artificial cerebrospinal fluid (ACSF; 2.0 mM KCl,125 mM NaCl, 1.2 mM MgSO4, 26 mM NaHCO3, 1.2 mM KH2PO4, 2.5 mM CaCl2 and 11 mM glucose). Parasagittal sections (300 μm) were cut using a vibrating microtome (Leica VT1000S, Leica Biosystems) at 4–5 °C in ACSF and the slices were pre-incubated in oxygenated ACSF at 30 °C for at least 60 min. Then one slice was laid down in the recording chamber (an 8 × 8 microelectrode array) submerged in ACSF (1 ml min−1) with temperature at 34 °C. MED64 system (Alpha MED Sciences, Panasonic) was used to record the fEPSPs in CA3 neurons by stimulating the mossy fibers from DG. LTP was induced by applying three trains of high-frequency stimulation (HFS; 100 Hz, 1-s duration), stimulation strength was set to 40% of the maximum obtained by plotting an input–output curve.
Spine analyses
Golgi staining for prefrontal cortex: The mice were deeply anesthetized and then fixed by transcardial perfusion with 0.5% NaNO2 followed by 4% formaldehyde and potassium dichromate with chloral hydrate which were mixed in 4% formaldehyde. After perfusion, the brains were postfixed in potassium dichromate with chloral hydrate mixed liquid for 3 days. Then the brains were moved into 1% AgNO3 solution for 3 days. Coronal sections of the brain were cut (100 μm thick) using Vibratome microtome (Leica, VT1000 S, Germany).
GFP-spine acquisition and analysis: The mice were anesthetized with an i.p. injection of 100 mg/kg of ketamine and 50 mg/kg of xylazine, and transcardially perfused with normal saline (NS), followed by 4% paraformaldehyde (PFA) for 30 min. Brains were removed and post-fixed for additional 48 h. After that, the brains were sliced 30 μm with a vibrating microtome (VT1000S, Leica, Germany). The slices were attached to slide glass, covered with 30% glycerol and coverslips. The spine image acquisition and analysis were performed as described in a previous study25. The excitatory neurons expressing non-fused GFP were used for spine counting. A Zeiss 100× immersion objective (Zeiss LSM710, Carl Zeiss AG, Oberkochen, Germany) was used to acquire images with 0.5 µm z-resolution.
Both Golgi staining and GFP-positive neuronal spine densities were determined in segments of dendrites at a distance of 90 μm from the soma, counted in z-stacks by manual scrolling of the images. Spine densities refer to the amount of spines per 10 μm dendrite length analyzed by using Imaris software (Bitplane, Zürich, Switzerland).
GSK-3β activity assay
The activity of GSK-3β was assayed using a kit (GMS50161.6, Genmed) by following the manufacturer’s instructions.
Statistics
Data were expressed as mean ± s.e.m. and analyzed using SPSS version 21.0 for Windows (SPSS Inc., Chicago, IL, USA) for The two–way repeated-measures ANOVA or Student’s t–test and GraphPad Prism 6.0 (GraphPad Software, Inc, La Jolla, CA) for Multiple t-test. The level of significance was set at p < 0.05.
Availability of data and material
The authors declare that the data supporting the findings of this study are available within the article and its Supplementary Information files, or from the authors upon request.
Ethics approval and consent to participate
All animal experiments were performed according to the ‘Policies on the Use of Animals and Humans in Neuroscience Research’ revised and approved by the Society for Neuroscience in 1995, and the animal study was approved by the Academic Review Board of Tongji Medical College, Huazhong University of Science and Technology.
References
Llorens-Martin, M., Jurado, J., Hernandez, F. & Avila, J. GSK-3beta, a pivotal kinase in Alzheimer disease. Frontiers in molecular neuroscience 7, 46 (2014).
Wang, J. Z., Wang, Z. H. & Tian, Q. Tau hyperphosphorylation induces apoptotic escape and triggers neurodegeneration in Alzheimer’s disease. Neuroscience bulletin 30, 359–366 (2014).
Beurel, E., Grieco, S. F. & Jope, R. S. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacology & therapeutics 148, 114–131 (2015).
Pei, J. J. et al. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. Journal of neuropathology and experimental neurology 56, 70–78 (1997).
Zhu, L. Q. et al. GSK-3 beta inhibits presynaptic vesicle exocytosis by phosphorylating P/Q-type calcium channel and interrupting SNARE complex formation. The Journal of neuroscience 30, 3624–3633 (2010).
Zhu, L. Q. et al. Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments. The Journal of neuroscience 27, 12211–12220 (2007).
Hernandez, F., Borrell, J., Guaza, C., Avila, J. & Lucas, J. J. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. Journal of neurochemistry 83, 1529–1533 (2002).
Dewachter, I. et al. GSK3beta, a centre-staged kinase in neuropsychiatric disorders, modulates long term memory by inhibitory phosphorylation at serine-9. Neurobiology of disease 35, 193–200 (2009).
Wang, Y. et al. Temporal correlation of the memory deficit with Alzheimer-like lesions induced by activation of glycogen synthase kinase-3. Journal of neurochemistry 106, 2364–2374 (2008).
Wang, Y. & Mandelkow, E. Tau in physiology and pathology. Nature reviews. Neuroscience 17, 5–21 (2016).
Medina, M. & Avila, J. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer’s disease. Current pharmaceutical design 16, 2790–2798 (2010).
Martinez, A. & Perez, D. I. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer’s disease? Journal of Alzheimer’s disease 15, 181–191 (2008).
Yuskaitis, C. J. et al. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochemical pharmacology 79, 632–646 (2010).
Contestabile, A. et al. Lithium rescues synaptic plasticity and memory in Down syndrome mice. The Journal of clinical investigation 123, 348–361 (2013).
Ly, P. T. et al. Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimer-associated phenotypes. The Journal of clinical investigation 123, 224–235 (2013).
Jiang, H., Guo, W., Liang, X. & Rao, Y. Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3beta and its upstream regulators. Cell 120, 123–135 (2005).
Salcedo-Tello, P., Ortiz-Matamoros, A. & Arias, C. GSK3 Function in the Brain during Development, Neuronal Plasticity, and Neurodegeneration. International journal of Alzheimer’s disease 2011, 189728 (2011).
Hur, E. M. & Zhou, F. Q. GSK3 signalling in neural development. Nature reviews. Neuroscience 11, 539–551 (2010).
Kim, W. Y. et al. GSK-3 is a master regulator of neural progenitor homeostasis. Nature neuroscience 12, 1390–1397 (2009).
Peineau, S. et al. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 53, 703–717 (2007).
Paul, J. R., Johnson, R. L., Jope, R. S. & Gamble, K. L. Disruption of circadian rhythmicity and suprachiasmatic action potential frequency in a mouse model with constitutive activation of glycogen synthase kinase 3. Neuroscience 226, 1–9 (2012).
Paul, J. R. et al. Regulation of persistent sodium currents by glycogen synthase kinase 3 encodes daily rhythms of neuronal excitability. Nature communications 7, 13470 (2016).
Hoeflich, K. P. et al. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406, 86–90 (2000).
Kimura, T. et al. GSK-3beta is required for memory reconsolidation in adult brain. PloS one 3, e3540 (2008).
Ochs, S. M. et al. Loss of neuronal GSK3beta reduces dendritic spine stability and attenuates excitatory synaptic transmission via beta-catenin. Molecular psychiatry 20, 482–489 (2015).
Bro, S. & Haycock, J. W. Visual cortex (translation of S. Ramon y Cajal) translated from L’Encorce Cerebrale Suivant les Regions L’Ecorce Visuelle, Chapter 25 in “Histologie du Systeme Nerveux de l’Homme et des Vertebres,” 1911. Behavioral biology 21, 508–528 (1977).
Andersen, P., Bliss, T. V., Lomo, T., Olsen, L. I. & Skrede, K. K. Lamellar organization of hippocampal excitatory pathways. Acta physiologica Scandinavica 76, 4A–5A (1969).
Skrede, K. K. & Westgaard, R. H. The transverse hippocampal slice: a well-defined cortical structure maintained in vitro. Brain research 35, 589–593 (1971).
Coulter, D. A. et al. Hippocampal microcircuit dynamics probed using optical imaging approaches. The Journal of physiology 589, 1893–1903 (2011).
Liu, X. et al. Optogenetic stimulation of a hippocampal engram activates fear memory recall. Nature 484, 381–385 (2012).
Teyler, T. J. & DiScenna, P. The hippocampal memory indexing theory. Behavioral neuroscience 100, 147–154 (1986).
Rudy, J. W. & O’Reilly, R. C. Contextual fear conditioning, conjunctive representations, pattern completion, and the hippocampus. Behavioral neuroscience 113, 867–880 (1999).
Chew, B. et al. Lentiviral silencing of GSK-3beta in adult dentate gyrus impairs contextual fear memory and synaptic plasticity. Frontiers in behavioral neuroscience 9, 158 (2015).
Patel, S. et al. Tissue-specific role of glycogen synthase kinase 3beta in glucose homeostasis and insulin action. Molecular and cellular biology 28, 6314–6328 (2008).
Nakashiba, T. et al. Young dentate granule cells mediate pattern separation, whereas old granule cells facilitate pattern completion. Cell 149, 188–201 (2012).
Rubin, S. A. et al. Borna disease virus-induced hippocampal dentate gyrus damage is associated with spatial learning and memory deficits. Brain research bulletin 48, 23–30 (1999).
Engin, E. et al. Modulation of anxiety and fear via distinct intrahippocampal circuits. eLife 5, e14120 (2016).
Rowe, M. K., Wiest, C. & Chuang, D. M. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neuroscience and biobehavioral reviews 31, 920–931 (2007).
Du, J. et al. A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proceedings of the National Academy of Sciences of the United States of America 107, 11573–11578 (2010).
Neves, G., Cooke, S. F. & Bliss, T. V. Synaptic plasticity, memory and the hippocampus: a neural network approach to causality. Nature reviews. Neuroscience 9, 65–75 (2008).
Hering, H. & Sheng, M. Dendritic spines: structure, dynamics and regulation. Nature reviews. Neuroscience 2, 880–888 (2001).
Wang, H., Hu, Y. & Tsien, J. Z. Molecular and systems mechanisms of memory consolidation and storage. Progress in neurobiology 79, 123–135 (2006).
Abel, T. & Lattal, K. M. Molecular mechanisms of memory acquisition, consolidation and retrieval. Current opinion in neurobiology 11, 180–187 (2001).
Sintoni, S., Kurtys, E., Scandaglia, M., Contestabile, A. & Monti, B. Chronic valproic acid administration impairs contextual memory and dysregulates hippocampal GSK-3beta in rats. Pharmacology, biochemistry, and behavior 106, 8–15 (2013).
Hu, S. et al. GSK3 inhibitors show benefits in an Alzheimer’s disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiology of disease 33, 193–206 (2009).
Coghlan, M. P. et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chemistry & biology 7, 793–803 (2000).
Takahashi, M., Tomizawa, K. & Ishiguro, K. Distribution of tau protein kinase I/glycogen synthase kinase-3beta, phosphatases 2A and 2B, and phosphorylated tau in the developing rat brain. Brain research 857, 193–206 (2000).
Kesner, R. P. & Rolls, E. T. A computational theory of hippocampal function, and tests of the theory: new developments. Neuroscience and biobehavioral reviews 48, 92–147 (2015).
Lee, I. & Kesner, R. P. Differential contributions of dorsal hippocampal subregions to memory acquisition and retrieval in contextual fear-conditioning. Hippocampus 14, 301–310 (2004).
Moser, M. B. & Moser, E. I. Functional differentiation in the hippocampus. Hippocampus 8, 608–619 (1998).
Sahay, A., Drew, M. R. & Hen, R. Dentate gyrus neurogenesis and depression. Progress in brain research 163, 697–722 (2007).
Cortes-Mendoza, J., D de Leon-Guerrero, S., Pedraza-Alva, G. & Perez-Martinez, L. Shaping synaptic plasticity: the role of activity-mediated epigenetic regulation on gene transcription. International journal of developmental neuroscience 31, 359–369 (2013).
Reis, C. R. et al. Crosstalk between Akt/GSK3beta signaling and dynamin-1 regulates clathrin-mediated endocytosis. The EMBO journal 34, 2132–2146 (2015).
Valvezan, A. J. & Klein, P. S. GSK-3 and Wnt Signaling in Neurogenesis and Bipolar Disorder. Frontiers in molecular neuroscience 5, 1 (2012).
Fanselow, M. S. & Gale, G. D. The amygdala, fear, and memory. Annals of the New York Academy of Sciences 985, 125–134 (2003).
Zhu, X. N. et al. Ephrin-B3 coordinates timed axon targeting and amygdala spinogenesis for innate fear behaviour. Nature communications 7, 11096 (2016).
Jiang, X. et al. CaMKII-dependent dendrite ramification and spine generation promote spatial training-induced memory improvement in a rat model of sporadic Alzheimer’s disease. Neurobiology of aging 36, 867–876 (2015).
Byth, L. A. Ca(2+)- and CaMKII-mediated processes in early LTP. Annals of neurosciences 21, 151–153 (2014).
Franklin, A. V. et al. Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice. Biological psychiatry 75, 198–206 (2014).
Hooper, C. et al. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. The European journal of neuroscience 25, 81–86 (2007).
Malenka, R. C. & Bear, M. F. LTP and LTD: an embarrassment of riches. Neuron 44, 5–21 (2004).
Yang, Y. et al. Opposite monosynaptic scaling of BLP-vCA1 inputs governs hopefulness- and helplessness-modulated spatial learning and memory. Nature communications 7, 11935 (2016).
Xie, A. J. et al. Cnga2 Knockout Mice Display Alzheimer’s-Like Behavior Abnormities and Pathological Changes. Molecular neurobiology 53, 4992–4999 (2016).
Walf, A. A. & Frye, C. A. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nature protocols 2, 322–328 (2007).
Acknowledgements
We thank Dr. James R Woodgett for GSK-3β floxed mice (GSK-3βlox/lox). This work was supported by grants from Natural Science Foundation of China (91632305, 81261120570 and 81528007), the Ministry of Science and Technology of China (2016YFC1305800), and the Ministry of Science and Technology of Hubei Province (2016CFA063).
Author information
Authors and Affiliations
Contributions
This study was initiated and designed by J.Z.W.; E.J.L., A.J.X. and M.Z.L. performed animal behavior studies; E.J.L. and Q.Z.Z. performed brain slice electrophysiology recordings and analyzed the data; E.J.L., A.J.X., M.Z.L., S.J.Z., S.H.L. and W.J.W. performed Western blotting, immunohistochemistry and GSK-3β activity assay; Q.W. and X.W. helped to collect data; J.Z.W. and E.J.L. analyzed the data and wrote the manuscript.
Corresponding author
Ethics declarations
Competing Interests
The authors declare that they have no competing interests.
Additional information
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Liu, E., Xie, AJ., Zhou, Q. et al. GSK-3β deletion in dentate gyrus excitatory neuron impairs synaptic plasticity and memory. Sci Rep 7, 5781 (2017). https://doi.org/10.1038/s41598-017-06173-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-017-06173-4
- Springer Nature Limited
This article is cited by
-
Humulus lupulus L. extract and its active constituent xanthohumol attenuate oxidative stress and nerve injury induced by iron overload via activating AKT/GSK3β and Nrf2/NQO1 pathways
Journal of Natural Medicines (2023)
-
Pharmacological intervention in young adolescents rescues synaptic physiology and behavioural deficits in Syngap1+/− mice
Experimental Brain Research (2022)
-
Enriched gestation activates the IGF pathway to evoke embryo-adult benefits to prevent Alzheimer’s disease
Translational Neurodegeneration (2019)
-
The TRAX, DISC1, and GSK3 complex in mental disorders and therapeutic interventions
Journal of Biomedical Science (2018)